+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency



Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency



Thrombosis and Haemostasis 116(1): 58-68



Severe congenital protein C (PC) deficiency (SCPCD) is associated with disseminated intravascular coagulation (DIC), purpura fulminans (PF), and vascular thromboembolic events (TE), often leading to organ failure and death. PC replacement therapy offers a safe, effective treatment for thromboembolic complications of SCPCD and secondary prophylaxis for recurrent DIC, PF, and TEs. A prospective, multi-centre, open-label, phase 2/3 study was conducted to demonstrate the safety and efficacy of protein C concentrate for treatment of PF and acute TEs. Fifteen enrolled patients with SCPCD received protein C concentrate; 11 received treatment for acute TEs (PF, 18 events; PF and other coumarin-related vascular thromboembolic events [coumarin-induced skin necrosis; CISN], 1 event; venous thrombosis, 5 events). Pre-defined efficacy criteria for treatment of acute TEs were compared with a historical control arm (i. e. patients receiving conventional therapy without protein C replacement). PF/CISN was demonstrated by pre-defined primary and secondary efficacy ratings. Primary ratings of protein C concentrate-treated episodes were significantly higher (p=0.0032) than in the historical control. For 19 PF/CISN episodes in 11 patients, 94.7 % of treatments were rated effective and 5.3 % effective with complications (not related to protein C concentrate). In a secondary efficacy rating, all treatments were rated effective (68.4 % excellent; 21.1 % good; 10.5 % fair). For 5/24 vascular thrombosis episodes, 80 % of treatments were rated excellent and 20 % were rated good. No treatment-related adverse events or serious adverse events occurred. In conclusion, protein C concentrate provides an efficacious, safe treatment for PF, CISN, and other TEs in SCPCD patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057738221

Download citation: RISBibTeXText

PMID: 27052576

DOI: 10.1160/th15-10-0786


Related references

The efficacy and safety of protein C concentrate Vapor-Heated in the treatment of severe congenital protein C deficiency with or without pupura fulminans. Blood 96(11 Part 1): 53a, 2000

Purpura fulminans in severe congenital protein C deficiency: Monitoring of treatment with protein C concentrate. European Journal of Pediatrics 155(1): 20-25, 1996

Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency. Journal of Pediatric Hematology/Oncology 26(1): 25-27, 2004

Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics 91(2): 418-422, 1993

Neonatal purpura fulminans without sepsis due to a severe congenital protein C deficiency. Archives de Pediatrie 22(10): 1027-1031, 2015

Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. New England Journal of Medicine 325(22): 1565-1568, 1991

Homozygous protein C deficiency presenting as neonatal purpura fulminans: management with fresh frozen plasma, low molecular weight heparin and protein C concentrate. Journal of Thrombosis and Thrombolysis 45(2): 315-318, 2018

Recombinant activated protein C is effective for purpura fulminans secondary to severe genetic protein C deficiency. Pediatric Research 53(4 Part 2): 297A, 2003

Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Critical Care Medicine 31(6): 1839-1847, 2003

Severe type I protein C deficiency with neonatal purpura fulminans due to a novel homozygous mutation in exon 6 of the protein C gene. Journal of Thrombosis and Haemostasis 4(5): 1152-1153, 2006

Purpura fulminans in a Chinese boy with congenital protein C deficiency. Pediatrics 77(5): 670-676, 1986

Retiform purpura is a sign of severe acquired protein C deficiency and risk of progression to purpura fulminans in sepsis and disseminated intravascular coagulation. Clinical Research 41(2): 253A, 1993

Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients. Critical Care 14(4): R156, 2010

Purpura fulminans. A cutaneous manifestation of severe protein C deficiency. Archives of Dermatology 124(9): 1387-1391, 1988

Severe autoimmune protein S deficiency in a boy with idiopathic purpura fulminans. British Journal of Haematology 89(3): 610-614, 1995